Mezlocillin: In Vitro Studies of a New Broad-Spectrum Penicillin
AUTOR(ES)
Bodey, Gerald P.
RESUMO
Mezlocillin is a new semisynthetic penicillin that inhibited 71% of the isolates of Serratia marcescens, 67% of Escherichia coli, 50% of Enterobacter spp., and 49% of Klebsiella spp. at a concentration of 12.5 μg/ml. It is also active against both indole-positive and -negative Proteus spp. and gram-positive cocci, except penicillin G-resistant Staphylococcus aureus. At a concentration of 100 μg/ml, it inhibited 94% of the isolates of Pseudomonas aeruginosa. It is more active than ampicillin, carbenicillin, and cephalothin against some gram-negative bacilli.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=351920Documentos Relacionados
- Laboratory Studies with a New Broad-Spectrum Penicillin, Pirbenicillin
- In vitro studies of BMY-28142, a new broad-spectrum cephalosporin.
- Pirbenicillin, a New Semisynthetic Penicillin with Broad-Spectrum Activity
- Pharmacokinetics of Bay k 4999, a New Broad-Spectrum Penicillin
- In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone.
